D
Daniil Stroiakovski
Researcher at Sheba Medical Center
Publications - 2
Citations - 2281
Daniil Stroiakovski is an academic researcher from Sheba Medical Center. The author has contributed to research in topics: Trametinib & Dabrafenib. The author has an hindex of 2, co-authored 2 publications receiving 1885 citations.
Papers
More filters
Journal ArticleDOI
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert,Boguslawa Karaszewska,Jacob Schachter,Piotr Rutkowski,Andrzej Mackiewicz,Daniil Stroiakovski,Michael Lichinitser,Reinhard Dummer,Florent Grange,Laurent Mortier,Vanna Chiarion-Sileni,Kamil Drucis,Ivana Krajsová,Axel Hauschild,Paul Lorigan,Pascal Wolter,Georgina V. Long,Keith T. Flaherty,Paul Nathan,Antoni Ribas,Antoni Ribas,Anne-Marie Martin,Peng Sun,Wendy A. Crist,Jeff Legos,Stephen D. Rubin,Shonda M Little,Dirk Schadendorf +27 more
TL;DR: Dabrafenib plus trametinib, as compared with vemurafenib monotherapy, significantly improved overall survival in previously untreated patients with metastatic melanoma with BRAF V600E or V600K mutations, without increased overall toxicity.
Journal ArticleDOI
Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials.
Dirk Schadendorf,Dirk Schadendorf,Georgina V. Long,Georgina V. Long,Georgina V. Long,Daniil Stroiakovski,Boguslawa Karaszewska,Axel Hauschild,Evgeny Levchenko,Vanna Chiarion-Sileni,Jacob Schachter,Claus Garbe,Caroline Dutriaux,Helen Gogas,Mario Mandalà,John B. A. G. Haanen,Céleste Lebbé,Andrzej Mackiewicz,Piotr Rutkowski,Jean-Jacques Grob,Paul Nathan,Antoni Ribas,Michael A. Davies,Ying Zhang,Mathilde Kaper,Bijoyesh Mookerjee,Jeffrey J. Legos,Keith T. Flaherty,Caroline Robert +28 more
TL;DR: Using the largest phase 3 data set available for BRAF/MEK inhibitor combination therapy in melanoma, results demonstrate that durable responses lasting ≥3 years are possible in subsets of patients with BRAF-mutant melanoma receiving D + T.